Free Trial

Unity Biotechnology 11/4/2024 Earnings Report

Unity Biotechnology logo
$0.96 -0.01 (-1.04%)
(As of 12/20/2024 05:40 PM ET)

Unity Biotechnology EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Unity Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Unity Biotechnology Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

This Indicator called BOTH NVDA rallies (Ad)

Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…

Click this link here. 

Unity Biotechnology Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Unity Software: What Really Matters For Long-Term Growth
See More Unity Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unity Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unity Biotechnology and other key companies, straight to your email.

About Unity Biotechnology

Unity Biotechnology (NASDAQ:UBX), a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

View Unity Biotechnology Profile

More Earnings Resources from MarketBeat

Upcoming Earnings